Search research articles
Contact Us
Filters
Showing results (51-60 of 98) with videos related to
Page
of 10
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
April 5, 2021
Mortality from Multiple Myeloma Within One Year Following Autologous Stem Cell Transplantation: Defining an Ultra-high Risk Population
Hannah M Cherniawsky, Hatem AlAhwal, Yasser Abou Mourad, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
September 28, 2010
Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning
Junya Kanda, David A Rizzieri, Cristina Gasparetto, et al.
Cancer Medicine
|
September 26, 2022
Real-world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database
Hira Mian, Richard LeBlanc, Martha Louzada, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 5, 2022
Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database
Hira Mian, Donna Reece, Esther Masih-Khan, et al.
Current Oncology (Toronto, Ont.)
|
March 24, 2022
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database
Arleigh McCurdy, Christopher P Venner, Esther Masih-Khan, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 4, 2019
Outpatient Autologous Stem Cell Transplants for Multiple Myeloma: Analysis of Safety and Outcomes in a Tertiary Care Center
Shruthi Ganeshappa Kodad, Heather Sutherland, Wasithep Limvorapitak, et al.
Haematologica
|
June 30, 2018
A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma
Jesús F San-Miguel, Maria-Asunción Echeveste Gutierrez, Ivan Špicka, et al.
Haematologica
|
October 15, 2020
The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database
Hannah M Cherniawsky, Vishal Kukreti, Donna Reece, et al.
European Journal of Haematology
|
June 15, 2021
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada
Donna E Reece, Esther Masih-Khan, Ehetu G Atenafu, et al.
Acta Haematologica
|
August 28, 2024
Real-World Impact of Routine Addition of Antithymocyte Globulin to Standard GVHD Prophylaxis in Myeloablative Unrelated Donor Transplants: Important Gains in Graft-versus-Host Disease Prevention though No Difference in Overall Survival
Ni Bai, Wasithep Limvorapitak, Robert Henderson, et al.
Page
of 10
Search research articles
Search
Showing results (51-60 of 98) with videos related to
Sort By:
Page
of 10
Clinical Lymphoma, Myeloma & Leukemia
|
April 5, 2021
Mortality from Multiple Myeloma Within One Year Following Autologous Stem Cell Transplantation: Defining an Ultra-high Risk Population
Hannah M Cherniawsky, Hatem AlAhwal, Yasser Abou Mourad, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
September 28, 2010
Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning
Junya Kanda, David A Rizzieri, Cristina Gasparetto, et al.
Cancer Medicine
|
September 26, 2022
Real-world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database
Hira Mian, Richard LeBlanc, Martha Louzada, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 5, 2022
Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database
Hira Mian, Donna Reece, Esther Masih-Khan, et al.
Current Oncology (Toronto, Ont.)
|
March 24, 2022
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database
Arleigh McCurdy, Christopher P Venner, Esther Masih-Khan, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 4, 2019
Outpatient Autologous Stem Cell Transplants for Multiple Myeloma: Analysis of Safety and Outcomes in a Tertiary Care Center
Shruthi Ganeshappa Kodad, Heather Sutherland, Wasithep Limvorapitak, et al.
Haematologica
|
June 30, 2018
A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma
Jesús F San-Miguel, Maria-Asunción Echeveste Gutierrez, Ivan Špicka, et al.
Haematologica
|
October 15, 2020
The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database
Hannah M Cherniawsky, Vishal Kukreti, Donna Reece, et al.
European Journal of Haematology
|
June 15, 2021
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada
Donna E Reece, Esther Masih-Khan, Ehetu G Atenafu, et al.
Acta Haematologica
|
August 28, 2024
Real-World Impact of Routine Addition of Antithymocyte Globulin to Standard GVHD Prophylaxis in Myeloablative Unrelated Donor Transplants: Important Gains in Graft-versus-Host Disease Prevention though No Difference in Overall Survival
Ni Bai, Wasithep Limvorapitak, Robert Henderson, et al.
Page
of 10